Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) and Appili Therapeutics (OTCMKTS:APLIF – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.
Profitability
This table compares Aclaris Therapeutics and Appili Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aclaris Therapeutics | -136.65% | -40.26% | -31.71% |
| Appili Therapeutics | N/A | N/A | -187.38% |
Insider and Institutional Ownership
98.3% of Aclaris Therapeutics shares are owned by institutional investors. 6.4% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 11.8% of Appili Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aclaris Therapeutics | $31.25 million | 5.87 | -$88.48 million | ($0.52) | -4.94 |
| Appili Therapeutics | $630,000.00 | 4.92 | -$2.80 million | ($0.02) | -1.28 |
Appili Therapeutics has lower revenue, but higher earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Appili Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Aclaris Therapeutics has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, Appili Therapeutics has a beta of -0.52, indicating that its stock price is 152% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and price targets for Aclaris Therapeutics and Appili Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aclaris Therapeutics | 0 | 0 | 6 | 1 | 3.14 |
| Appili Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
Aclaris Therapeutics presently has a consensus target price of $11.00, indicating a potential upside of 328.02%. Given Aclaris Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Aclaris Therapeutics is more favorable than Appili Therapeutics.
Summary
Aclaris Therapeutics beats Appili Therapeutics on 9 of the 15 factors compared between the two stocks.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
About Appili Therapeutics
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
